DIAGNOSTIC LABORATORY SERVICES, INC.

Antimicrobial Susceptibility Profile (January 2021 - December 2021)
Outpatient Only

NOTE: Statistics include data from patients seen in the medical centers through the Emergency Department, Ambulatory and Clinics.

GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)

Cefazolin (urine) limited to *E. coli, K.pneumoniae* and *P.mirabilis*	*Achromobacter xylosoxidans*		*Acin.baumannii complex* [a]		*Citro. freundii* complex [b]		*Citrobacter koserii*		*Klebsiella (Ent) aerogenes* [c]		*Ent. cloacae* complex [d]		*Escherichia coli*		*E. coli* (ESBL)		*Klebsiella oxytoca*		*Klebsiella pneumoniae*		*Kleb pneumo* (ESBL)		*Klebsiella variicola*		*Morganella morganii*		*Proteus hauseri*		*Proteus mirabilis*		*Providencia rettgeri*		*Pseudo aeruginosa*		*Serratia marcescens*	
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun (4 ESBL)	Jul-Dec (2 ESBL)	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun (10 ESBL)	Jul-Dec (9 ESBL)	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec
Amikacin	13	14			100	99	100	100	100	100	100	100	100	100	100	100	100	100	100	100	99	100	100	100	100	100	100	*	100	100	100	*	99	100	100	100
Ampicillin													65	65															93	94						
Ampicillin/Sulbactam			100	99									87	89			87	96	92	94			95	94	9	19	100	*	98	98	77	*				
Cefazolin (urine)													97	97					99	99			100	67					99	99						
Cefepime	29	29	98	97	100	100	100	100	100	100	100	97	100	100			100	100	100	100			100	100	100	100	100	*	100	100	100	*	98	98	100	100
Ceftazidime	90	88	100	97																													98	98		
Ceftriaxone	0	0	90	83	88	87	98	98	91	93	85	81	99	99			98	100	100	100			100	98	96	99	97	*	99	99	100	*			99	96
Ciprofloxacin	37	52	100	96	92	88	99	98	99	99	98	91	84	85	14	15	93	100	96	97	20	20	97	92	94	88	100	*	96	95	92	*	94	93	94	93
Ertapenem					100	100	100	100	99	99	100	99	100	100	100	100	100	100	100	100	98	99	100	100	100	100	100	*	100	100	100	*			100	100
Gentamicin	0	4	100	99	99	99	100	100	99	100	100	95	94	94	75	72	100	99	100	100	73	80	100	100	98	94	100	*	99	98	100	*	99	100	100	100
Imipenem	97	97	100	99											100	100					100	100											94	94		
Levofloxacin	86	76	100	97	91	89	100	100	99	99	100	93	85	85	9	10	96	100	98	98	28	22	99	99	96	90	100	*	96	95	91	*			97	95
Nitrofurantoin (urine)					99	99	99	99	45	45	85	81	99	99	96	98	97	100	64	77	23	57	96	92												
Piperacillin/Tazobactam	97	100	85	93	100	100	100	100	96	93	89	87	99	100	98	98	97	99	99	99	84	88	100	100	100	100	100	*	100	100	97	*			100	100
Tobramycin	0	4	100	99	100	100	100	100	100	100	100	97	99	100	87	91	100	99	100	100	68	69	100	100	100	99	100	*	100	100	100	*	100	100	100	99
Trimeth-Sulfa	97	84	97	93	93	85	100	100	97	99	100	85	83	83	41	45	93	96	94	94	18	21	95	94	93	90	100	*	91	90	84	*			100	100
Total Isolates	37	31	60	74	74	79	238	232	150	171	46	191	7331	7327	777	750	92	80	1610	1549	92	111	88	85	142	118	33	21	815	733	37	22	881	898	86	83
													ESBL Rates		10%	9%	4%	2%			5%	7%							1%	1%						

a *Acinetobacter baumanni* complex includes *A.calcoacecus, A.baumannii, A.dijkshoomiae, A.nosocomialis, A.pittii* and *A. seifertii*

b *Citrobacter freundii* complex includes *C.braaki, C.freundii, C.gillenii, C.murliniae, C.rodenticum, C.sedlakii* and *C.wekmenii*

c *Enterobacter aerogenes* has been renamed *Klebsiella aerogenes*

d *Enterobacter cloacae* complex includes *E.asburiae, E.cancerogenus, E.cloacae, E.dissolvens, E.hormaechei, E.kobei* and *E.nimipressuralis*

GRAM POSITIVE SUSCEPTIBILITIES (Percent Susceptible)

S.aureus complex includes *S.aureus, S.argenteus* and *S.schweitzeri*	*S,aureus* [3] complex MSSA [4]		*S. aureus* [3] complex MRSA		*Staph* sp. [3] (coag neg)		*Enterococcus* Non-VRE [5]		*Enterococcus* VRE		*Streptococcus agalactiae*		*Streptococcus pneumoniae*		*Streptococcus pyogenes*	
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec
Ampicillin							98	98	*	*						
Cefazolin	100	100			54	61										
Cefotaxime													*	*		
Cetriaxone											100	100	See Table		100	100
Ciprofloxacin (urine)							91	92	*	*						
Clindamycin [1, 2]	86	85	65	65	68	66					66	62	*	*	85	80
Daptomycin	100	100	100	100	100	99										
Erythromycin	76	76	25	27	46	46					57	55	*	*	83	79
Levofloxacin (urine)							91	92	*	*			*	*		
Linezolid	100	100	100	100	100	100	99	100	*	*						
Minocycline	100	100	99	100	100	100										
Moxifloxacin	95	96	56	60	78	83							*	*		
Nitrofurantoin (urine)	100	100	100	100	99	100	99	100	*	*						
Oxacillin	100	100			54	61										
Penicillin	41	41			22	27					100	100	See Table		100	100
Rifampin [3]	100	100	99	100	99	99										
Tetracycline [6]	92	92	84	82	81	84	26	28	*	*			*	*		
Trimeth-Sulfa	97	97	63	59	77	78							*	*		
Vancomycin	100	100	100	100	100	100	100	99	*	*	100	100	*	*	100	100
Total Isolates	1699	1650	739	755	851	866	1056	1001	20	22	90	102	14	14	635	671
	MRSA Rate		30%	31%			VRE Rate		2%	2%						

Footnotes:

[1] Clindamycin & Erythromycin are not appropriate for urine sources

[2] Erythromycin is not appropriate for pregnant women

[3] Rifampin should not be used alone for treatment of *Staph* infections

[4] *Staph aureus* (MSSA) isolates that show Penicillin susceptibility may harbor the blaZ gene that produces beta-lactamase.

[5] Non-VRE includes intrnsically resistant *Enterococcus* (*E. casseliflavus* & *E.gallinarum*)

[6] For urine only with isolates of *Enterococcus*

Streptococcus pneumoniae					
Ceftriaxone			Peniclin		
MIC	# isolates S.pneumoniae		MIC	# isolates S.pneumoniae	
	Jan-Jun	Jul-Dec		Jan-Jun	Jul-Dec
<=0.12	*	*	<=0.06	*	*
0.25	*	*	0.12	*	*
0.5	*	*	0.25	*	*
1	*	*	0.5	*	*
2	*	*	1	*	*
>=4	*	*	2	*	*
			4	*	*
			>=8	*	*

S. pneumoniae interpretive guidelines

Penicillin		
Parenteral non-meningitis		
<=2 S	4 I	>=8 R
Parenteral meningitis		
<=0.06 S	----	>=0.12 R
Oral		
<=0.06 S	0.12-1 I	>=2 R
Ceftriaxone		
Non-meningitis		
<=1 S	2 I	>=4 R
Meningitis		
<=0.5 S	1 I	>=2 R

Stenotrophomonas maltophilia	Jan-Jun	Jul-Dec
Levofloxacin	92	92
Trimethoprim/Sulfa	96	100
Ceftazidime *	27	n/a
Total Isolates	51	39

* Ceftazidime resulted if Trimeth/Sulfa is Resistant

Haemophilus influenzae	Jan-Jun	Jul-Dec
Ampicillin	*	*
Azithromycin	*	*
Cetriaxone	*	*
Cefuroxime	*	*
Meropenem	*	*
Moxifloxacin	*	*
Tetracycline	*	*
Total Isolates	26	29

Asterisk (*) indicates no result available

Where isolates in both periods are >=30, the following apply:

Green indicates increase in susceptibility by >5%

Red indicates decrease in susceptibility by >5%

NOTE: Where total isolates is less than 30, the susceptibility percentage may not be clinically significant and are highlighted in BLUE on these tables.
Source: CLSI Document M39-A4, January 2014

Data compiled by the Microbiology Department at Diagnostic Laboratory Services, Inc. January 2022 (c)